BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent
-
Stock markets sink as Trump eyes tariffs on EU, Apple
-
Fur-st prize for Icelandic sheepdog at Cannes canine competition
-
Leningrad Siege survivor, 84, fined over peace placard
-
Leclerc tops first Monaco practice after early collision
-
Tuchel won't let England stars leave early for Club World Cup
-
Sabalenka feeling 'stronger than ever' on clay before French Open
-
Trump fires new tariff threats at Apple and EU
-
Penaud recovers from injury to start Champions Cup final
-
France's TotalEnergies to face court in June in 'greenwashing' case
-
Man City back plea to reduce squad size: Guardiola
-
Napoleon's sword sold at auction for 4.7 mn euros
-
European stocks sink as Trump puts EU in tariff crosshairs
-
Merz, Xi discuss Ukraine war, trade woes amid global 'chaos'
-
Iran, US hold new round of nuclear talks in Rome
-
Cook strikes on debut after England run riot against Zimbabwe
-
Defendants ask forgiveness ahead of Kardashian robbery verdict
-
Bangladesh minister says Yunus 'not going to step down'
-
260 miners stuck underground after 'incident' at S.African shaft
-
S.Africa minister rejects 'genocide' claim with statistics
-
Lucu's Bordeaux-Begles eye 'neutralising' Pollock in Champions Cup final
-
Departing Ancelotti wishes Alonso luck as his Real Madrid successor
-
Chelsea can cope with pressure of top-five battle, says Maresca
-
Brook's quickfire fifty takes England to 565-6 dec against Zimbabwe
-
Alexander-Arnold 'deserves' his part in Liverpool title party: Slot
-
Missing out on Champions League would be huge blow: Newcastle boss Howe
-
Fire walkers defy pain in ancient Greek ritual
-
Stocks firm, dollar drops at end of rocky week
-
Dismayed Chinese students ponder prospects after Trump Harvard ban
-
Slot unsure if Alexander-Arnold will play in Liverpool season finale
-
Helmsman of cargo ship run aground in Norway was likely asleep: reports
-
Sri Lanka's ex-skipper Mathews to quit Test cricket
-
Ban on ousted ex-ruling party divides Bangladesh voters
-
UK newspaper The Telegraph set for US ownership
-
President vows oil won't threaten Suriname's carbon negative status
-
Saudi-based Toney recalled to England squad by Tuchel
-
Son's European 'milestone' shows South Korea strength - FA
-
Stocks bounce after Treasury-led sell-off
-
German growth upgraded on pre-tariff export surge
-
Flood victims confront damage after record deluge in eastern Australia
-
Stocks mixed after Treasury-led sell-off
-
Iran, US to hold new round of nuclear talks in Rome
-
Fears for crops as drought hits northern Europe
-
UFC champ Zhang says acting 'experiment' and fighting not so different
-
British king to visit Ottawa amid Trump-Canada tension
-
Cannes maitre d'hotel retires with memories of stars
-
Franco symbols mark Spanish streets 50 years after dictator's death
-
Blaze-hit Athens suburb trains to tackle new fire season
-
Thai athlete, 105, unrivalled but not lonely at World Masters Games
-
Japan core inflation tops forecasts as rice prices almost double
-
Row erupts as German city plans safe room for crack addicts
NYSE - LSE
| CMSC | 0.05% | 21.97 | $ | |
| RYCEF | -0.27% | 11.28 | $ | |
| SCS | -0.94% | 10.055 | $ | |
| VOD | -2.43% | 10.29 | $ | |
| RIO | 0.5% | 61.43 | $ | |
| BTI | 0.73% | 44.93 | $ | |
| NGG | -0.18% | 73.5 | $ | |
| GSK | -0.44% | 38.75 | $ | |
| BCE | -0.12% | 21.445 | $ | |
| RELX | 0.81% | 55.43 | $ | |
| RBGPF | 4.83% | 66.2 | $ | |
| CMSD | -0.05% | 21.72 | $ | |
| BP | -0.66% | 28.75 | $ | |
| AZN | 0.54% | 70.33 | $ | |
| JRI | -0.59% | 12.566 | $ | |
| BCC | -1.55% | 86 | $ |
BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent
VANCOUVER, BC / ACCESS Newswire / May 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the examining division of the European Patent Office ("EPO") has provided formal notice of the EPO's intention to grant BioNxt its core patent without significant changes.
The Company's core patent filing was a comprehensive application for the sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases. This patent family provides numerous proprietary product development and commercialization opportunities, including BioNxt's lead product, BNT23001, a sublingual thin-film formulation of Cladribine for the treatment of multiple sclerosis (MS).
"Confirmation of the Company's flagship intellectual property asset in Europe is a major milestone for BioNxt," stated Hugh Rogers, CEO of BioNxt. "We expect the European patent grant to be finalized and published in the coming weeks. The timing is excellent as we can confidently prepare for the upcoming BNT23001 human bioequivalence study in Europe."
BioNxt continues to advance the nationalization phase of the patent protection process at the European Patent Office and Eurasian Patent Organization, as well as with independent filing nations, such as Australia (AU), Canada (CA), New Zealand (NZ), USA (US), and Japan (JP). Securing nation-level patents around the globe will serve as the foundation for commercial opportunities for the Company's pipeline of sublingual products targeting autoimmune diseases such as multiple sclerosis (MS), myasthenia gravis (MG), lupus nephritis (LN) and rheumatoid arthritis (RA).
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: [email protected]
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
D.Kaufman--AMWN